The dose-dependent AβO reduction is a positive pharmacodynamic signal for PMN310's mechanism, but the data are from healthy volunteers, not Alzheimer's patients. The key catalyst is the upcoming six-month blinded interim data from the Phase 1b PRECISE-AD trial, which will provide the first look at safety and biomarker trends in the target population. Traders should watch for that release in the coming weeks.
Price Chart
Executive Summary
ProMIS Neurosciences announced at AAIC 2026 that its lead Alzheimer's candidate, PMN310, demonstrated a dose-dependent reduction of amyloid-beta oligomers (AβO) in cerebrospinal fluid from healthy volunteers in its Phase 1a trial. This is one of the first quantitative measures of treatment-related oligomer reduction in humans, providing pharmacodynamic evidence of target engagement. The company is on track to present six-month blinded interim data from its Phase 1b PRECISE-AD trial in the coming weeks, with top-line unblinded results expected in early Q1 2027.
Key Facts
- PMN310 showed dose-dependent reduction of AβO in CSF at 3 and 29 days after a single dose in healthy volunteers (Phase 1a, NCT06105528).
- AβO was measured using the sFIDA assay developed by attyloid GmbH, providing direct quantification of oligomer particles.
- PMN310 demonstrated strict selectivity for AβO with no binding to monomers, plaques, or vascular deposits.
- CSF half-life of PMN310 is approximately 27 days, with concentrations 100–600 times the estimated molar concentration of AβO.
- Blinded six-month interim data from the Phase 1b PRECISE-AD trial expected in the coming weeks; top-line unblinded results expected early Q1 2027.
- PMN310 was granted Fast Track Designation by the FDA in July 2025.
Financial Impact
No financial figures disclosed in the press release.
Risk Factors
- Phase 1a data in healthy volunteers may not translate to Alzheimer's patients.
- Blinded interim data may be inconclusive or show no clear trends.
- Competition from approved anti-amyloid antibodies (e.g., Leqembi, donanemab) with established safety profiles.
- Small market cap ($115M) and early-stage pipeline increase binary risk around clinical data readouts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3326583 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 3 | $9.12 $9.15 | ▲ +0.33% | ▲ +0.75% | $8.52 (−6.58%) |
Oct 6, 2026 21d ago | Press Release | $9.21 $9.12 | ▼ −0.98% | ▼ −0.74% | $8.52 (−7.49%) |
Sep 1, 2026 8w ago | Press Release | $13.35 $13.98 | ▲ +4.68% | ▲ +4.24% | $8.52 (−36.18%) |
Jul 14, 2026 15w ago | Press Release | $13.66 $14.01 | ▲ +2.53% | ▲ +2.13% | $8.52 (−37.63%) |
May 28, 2026 21w ago | Press Release | $10.87 $10.81 | ▼ −0.55% | ▼ −0.79% | $8.52 (−21.62%) |
May 12, 2026 24w ago | 8-K | $10.49 $10.57 | ▲ +0.76% | ▲ +0.19% | $8.52 (−18.78%) |
Apr 3, 2026 29w ago | EFFECT | $10.96 $10.88 | ▲ +0.73% | ▲ +0.79% | $8.52 (+22.26%) |
Mar 25, 2026 30w ago | S-3 | $15.13 $14.74 | ▲ +2.58% | ▲ +0.90% | $8.52 (+43.69%) |
Mar 18, 2026 31w ago | S-3 | $18.21 $17.60 | ▲ +3.35% | ▲ +1.61% | $8.52 (+53.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers